Advertisement
New Zealand markets close in 3 hours 45 minutes
  • NZX 50

    11,816.78
    -19.26 (-0.16%)
     
  • NZD/USD

    0.5887
    -0.0019 (-0.32%)
     
  • NZD/EUR

    0.5531
    -0.0013 (-0.24%)
     
  • ALL ORDS

    7,821.30
    -77.60 (-0.98%)
     
  • ASX 200

    7,563.70
    -78.40 (-1.03%)
     
  • OIL

    83.80
    +1.07 (+1.29%)
     
  • GOLD

    2,398.90
    +0.90 (+0.04%)
     
  • NASDAQ

    17,394.31
    -99.31 (-0.57%)
     
  • FTSE

    7,877.05
    +29.06 (+0.37%)
     
  • Dow Jones

    37,775.38
    +22.07 (+0.06%)
     
  • DAX

    17,837.40
    +67.38 (+0.38%)
     
  • Hang Seng

    16,385.87
    +134.03 (+0.82%)
     
  • NIKKEI 225

    37,302.65
    -777.05 (-2.04%)
     
  • NZD/JPY

    90.8450
    -0.4090 (-0.45%)
     

What Are Insys Therapeutics’ Top Priorities?

What Are Insys Therapeutics’ Top Priorities?

Insys (INSY) is taking strategic steps to restore stakeholder confidence. The company aims to achieve one NDA (or new drug application) per year over the next five years. Insys is targeting treatments for orphan diseases, neurological diseases like pediatric epilepsy, genetic conditions like Prader-Willi syndrome, and treatments for secondary allergic reactions, anorexia, and products for opioid overdose.